Clinical validation study of circulating tumour DNA in patients with advanced melanoma treated with dabrafenib or dabrafenib plus trametinib

BACKGROUND: Melanoma lacks validated blood-based biomarkers for monitoring and predicting treatment efficacy. Cell-free circulating tumour DNA (ctDNA) is a promising biomarker; however, various detection methods have been used, and, to date, there have been no large studies examining the association...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Lancet Oncol
Autors principals: Syeda, Mahrukh M, Wiggins, Jennifer M, Corless, Broderick C, Long, Georgina V, Flaherty, Keith T, Schadendorf, Dirk, Nathan, Paul D, Robert, Caroline, Ribas, Antoni, Davies, Michael A, Grob, Jean Jacques, Gasal, Eduard, Squires, Matthew, Marker, Mahtab, Garrett, James, Brase, Jan C, Polsky, David
Format: Artigo
Idioma:Inglês
Publicat: 2021
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC8034833/
https://ncbi.nlm.nih.gov/pubmed/33587894
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(20)30726-9
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars